Cubist Pharmaceuticals
Cubist Pharmaceuticals, Inc. is a biopharmaceutical company that focuses on the research, development, and commercialization of innovative pharmaceutical products aimed at addressing unmet medical needs in acute care settings. The company markets CUBICIN (daptomycin for injection), a pioneering antibiotic in the lipopeptide class, as well as ENTEREG (alvimopan), which is designed to enhance gastrointestinal recovery following bowel surgery. Additionally, Cubist promotes MERREM I.V. (meropenem for injection), an established broad-spectrum antibiotic. The company's product pipeline includes several candidates in various stages of clinical trials, such as ecallantide for treating severe allergic reactions and therapies targeting Clostridium difficile-associated diarrhea and multi-drug resistant Gram-negative infections. In collaboration with Alnylam Pharmaceuticals, Cubist is also developing novel treatments for respiratory syncytial virus infections utilizing RNA-interference technology. Founded in 1992 and headquartered in Lexington, Massachusetts, Cubist remains committed to advancing acute care therapies for hospitals and healthcare providers.
Optimer Pharmaceuticals, Inc. (Optimer) is a biopharmaceutical company focused on discovering, developing and commercializing anti-infective products. It has two late-stage anti-infective product candidates, fidaxomicin and Pruvel (prulifloxacin). Optimer's development efforts are focused on products that treat gastrointestinal infections, and related diseases where therapies have limitations. Its product portfolio includes Fidaxomicin, Pruvel, CEM-101, OPT-822/OPT-821 Combination Therapy and OPT-88.
Trius Therapeutics is a biopharmaceutical company based in San Diego, California, dedicated to the discovery, development, and commercialization of innovative antibiotics aimed at treating life-threatening infections. The company has successfully completed two Phase 3 clinical trials for its lead product, Tedizolid Phosphate, a second-generation oxazolidinone designed for the treatment of serious gram-positive bacterial infections, including those caused by methicillin-resistant Staphylococcus aureus (MRSA). As bacterial resistance to existing antibiotics continues to rise, the need for new therapeutics to combat multi-drug resistant infections becomes increasingly urgent. Trius Therapeutics is led by a skilled management team with extensive experience in drug development and regulation, contributing to the company's efforts to address critical healthcare challenges posed by antibiotic resistance.
Adolor Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of prescription pain and pain-management products. ENTEREG (alvimopan) is the United States Food and Drug Administration (FDA) approved product. ENTEREG is indicated to accelerate upper and lower gastrointestinal (GI) recovery following partial large or small bowel resection surgery with primary anastomosis. The Company is conducting two Phase 2 clinical trials of ADL5945 to treat opioid-induced constipation (OIC), a condition that often results from long-term use of opioid analgesics in the management of chronic pain conditions. In addition, it is continuing development efforts on ADL7445, a second peripherally-acting mu opioid receptor antagonist, which is considered a back-up compound in its OIC program. The Company has completed Phase 1 clinical evaluation of ADL6906 (beloxepin).
Calixa Therapeutics, Inc. is a privately-held biopharmaceutical company focused on the development of a novel cephalosporin to address the expanding problem of multi-drug resistant organisms. Treatment of infections caused by resistant gram-negative bacteria, especially Pseudomonas aeruginosa, is recognized as an unmet medical need by the infectious diseases community. Calixa’s lead product, CXA-101, is an IV formulation of a novel cephalosporin that has excellent potency especially against multi-drug resistant Pseudomonas aeruginosa, which differentiates it from other cephalosporins. No similar drug is known to be in development. Calixa plans to combine this product with a β-lactamase inhibitor; the combination product (CXA-201) has the potential to become the first-line therapeutic choice for hospitalized patients suffering from serious infection caused by gram-negative organisms.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.